公司业绩 - 太平洋生物科学公司(PACB)2024年第一季度每股亏损0.26美元 与Zacks共识预期一致 较去年同期每股亏损0.31美元有所改善 [1] - 上季度实际每股亏损0.27美元 优于预期的0.31美元 超出预期12.9% 过去四个季度中有三次超过EPS预期 [2] - 第一季度营收3881万美元 略超Zacks共识预期0.08% 与去年同期3890万美元基本持平 过去四个季度均超过营收预期 [3] 市场表现 - 公司股价年初至今下跌82.9% 同期标普500指数上涨8.8% [5] - 当前Zacks评级为2级(买入) 预计短期内将跑赢大盘 [8] 未来展望 - 下季度共识预期为每股亏损0.24美元 营收5191万美元 本财年预期每股亏损1美元 营收1.8282亿美元 [9] - 业绩电话会议中管理层的评论将影响股价短期走势 [4] - 盈利预期修订趋势目前向好 但可能随最新财报发布而调整 [8] 行业情况 - 所属医疗仪器行业在Zacks行业排名中位列前37% 研究显示前50%行业表现优于后50% 幅度超过2:1 [10] - 同业公司DarioHealth预计5月15日公布季报 预期每股亏损0.59美元 同比恶化231.1% 营收预期595万美元 同比下降15.8% [11][12]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________________ Form 10-Q _____________________________________________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCH ...

费用降低计划 - 公司于2024年3月31日的季度结束时，宣布计划通过非GAAP基础将年化运营费用降低5,000万至7,500万美元，以更好地与战略倡议相匹配[5] - 公司无法确定与这些行动相关的费用金额或范围，将在能够估计公司预计将发生的费用时通过修订此8-K表格提供进一步细节[5] 财务报表 - 公司的财务报表截至2024年3月31日的季度尚未最终确定或审计，因此该期间的最终结果可能与新闻稿中包含的未经审计初步财务信息有实质差异[9]

Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, is scheduled to release first-quarter 2024 results on May 9.In the last reported quarter, the company’s adjusted loss per share of 27 cents was narrower than the Zacks Consensus Estimate of a loss of 31 cents per share. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, delivering an earnings surprise of 13.1%, on average.Let’s see how things have shaped up prior to this announc ...

Pacific Biosciences of California (PACB) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this maker of genetic analysis technology have returned -49.7% over the past month versus the Zacks S&P 500 composite's -4.2% change. The Zacks Medical - Instruments industry, to which Pacific Biosciences belongs, has lost 4.3% over this period. Now the key question is: Where could the st ...

Pacific Biosciences of California (PACB) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by th ...

Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, recently announced preliminary revenues for first-quarter 2024. Despite the soft preliminary results, the company’s shares gained 7.1% in the pre-market trading session.The company is scheduled to release first-quarter results on May 9.Per the preliminary report, first-quarter 2024 total revenues are estimated to be $38.8 million, down 0.3% year over year. The Zacks Consensus Estimate of $50 million lies above the preliminary figure ...

文章核心观点 - 公司第一季度收入低于预期,主要原因包括客户推迟仪器购买、耗材出货疲软等 [6][7][8][9] - 公司预计2024年全年收入将在170-200百万美元之间,低于此前预期 [11] - 公司计划通过成本削减措施,将2024年全年非GAAP经营费用降低5000-7500万美元 [10] - 公司表示长期增长前景仍然看好,正在采取措施提高商业执行力、提升毛利率等 [10][11] 根据目录分类总结 财务数据 - 第一季度初步收入为3880万美元,与上年同期基本持平 [2] - 其中仪器收入1900万美元,耗材收入1600万美元,服务及其他收入380万美元 [2][3] - 第一季度共出货28台Revio测序系统,截至3月31日累计安装201台 [4] - 截至3月31日,公司现金及投资余额约为5.62亿美元 [5] 业务表现 - 公司认为客户推迟仪器购买、耗材出货疲软等因素导致第一季度业绩低于预期 [6][7][8][9] - 公司表示将采取措施提高商业执行力,推动Revio和Onso平台的市场渗透 [10] - 公司预计第二季度收入将好于第一季度,下半年随着耗材收入恢复增长而有所改善 [11] 未来展望 - 公司预计2024年全年收入将在170-200百万美元之间,低于此前预期 [11] - 公司计划通过成本削减措施,将2024年全年非GAAP经营费用降低5000-7500万美元 [10] - 公司表示长期增长前景仍然看好,正在采取措施提高毛利率等 [10][11] - 公司表示可能无法在2026年实现至少5亿美元的收入目标,正在重新评估实现该目标的时间 [12]

Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, has been gaining from its slew of strategic deals over the past few months. The optimism, led by a solid fourth-quarter 2023 performance and its product development activities, is expected to contribute further. However, stiff competition and macroeconomic concerns persist.Over the past year, this currently Zacks Rank #3 (Hold) stock has lost 70.5% against the 10.1% growth of the industry. The S&P 500 rose 24.9% in the same time fra ...

MENLO PARK, Calif., March 22, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the "Option") covering an aggregate of 79,600 shares of PacBio common stock and restricted stock units ("RSUs") covering 39,800 shares of PacBio common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity In ...